Jared Weiss, MD highlights the success of a grant that led to a patient’s first CAR infusion. Key topics include the importance of comprehensive biomarker testing in non-squamous lung cancer patients and the impact of targeted therapies on survival and quality of life. Weiss emphasizes the need for optimal supportive care and discusses new drug developments, including antibody drug conjugates and bi-specific T-cell engagers, which hold promise for improving patient outcomes in thoracic oncology.